Minerva Neurosciences Names Remy Luthringer As Executive Chairman & William Doyle As Lead Independent Director

Minerva Neurosciences recently named Remy Luthringer, PhD, as its new executive chairman and William Doyle as its new lead independent director. The new appointments comes in the wake of Marc Beer resigning as the chairman of the company’s Board of Directors.

In his new role, Dr. Luthringer will lead the implementation of Minerva’s commercial strategy, which is focused on MIN-101—the company’s treatment intended for the negative symptoms of schizophrenia—which is currently in Phase 3 clinical testing. Mr. Doyle will offer his industry experience in the realms of strategic development, partnering, product launches, marketing, and . . .